Royalty Pharma PLC (DE:RPD)

NASDAQ:RPD

RPD

Royalty Pharma

RESEARCH TOOLSreports

Royalty Pharma (RPD) Price & Analysis

5 Followers

RPD Stock Chart & Stats

€40.18

€0.39(1.60%)

At close: Jan 08 4:00 PM EST

€40.18

€0.39(1.60%)

Day’s Range― - ―

52-Week Range€28.87 - €49.00

Previous CloseN/A

Volume0.00

Average Volume (3M)175.00

Market Cap

€26.59B

Enterprise Value€31.47B

Total Cash (Recent Filing)€608.29M

Total Debt (Recent Filing)€8.96B

Price to Earnings (P/E)27.6

Beta0.18

Next Earnings

Aug 12, 2026

EPS Estimate

1.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.46

Shares Outstanding443,274,100

10 Day Avg. Volume115

30 Day Avg. Volume175

Financial Highlights & Ratios

PEG Ratio0.78

Price to Book (P/B)2.58

Price to Sales (P/S)7.02

P/FCF Ratio6.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€51.80

Price Target Upside28.93% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)4.5

Revenue Forecast (FY)€3.03B

Bulls Say, Bears Say

Bulls Say

Cash GenerationVery strong and consistent cash generation provides durable capacity to fund acquisitions, support dividend increases and buybacks, and service interest. High FCF to net income and cash coverage (~4.9x) materially improve financial flexibility even if revenue timing fluctuates.

Recurring Royalty GrowthRecurring royalty receipts driven by multiple commercial products (e.g., Tremfya, Voranigo, Evrysdi) underpin predictable, long‑dated cash flows. That diversification across therapies and steady organic growth reduce reliance on single assets and support multi‑year revenue visibility.

Balance Sheet & LiquidityLong debt duration, an upgraded credit rating, and an undrawn revolver create durable access to capital for new royalty buys and co‑funding. The mix supports strategic dealmaking while covenant discipline and liquidity cushion reduce refinancing pressure over the medium term.

Bears Say

Elevated Interest ExpenseMaterial interest outlays are a persistent cash drag given sizeable debt stock. Semiannual timing swings can compress quarterly cash available for reinvestment or distributions, and higher-for-longer rates would structurally increase financing costs and reduce net cash returns.

Decline In Milestone ReceiptsMilestones are lumpy upside to returns; a sustained reduction cuts non‑recurring upside and makes growth more reliant on existing royalties and M&A. Lower milestone cadence reduces optional upside and complicates multi‑year cash‑flow modeling.

Execution And Optionality Risk In Co‑fundingDependence on partner choices for tranche draws creates uncertainty in deal realization and expected returns. Scaling co‑funding is operationally complex and optional tranches can leave projected royalty streams contingent, elevating execution risk to medium‑term growth plans.

Royalty Pharma News

Royalty Pharma Shareholders Back Board, Pay and Flexibility

Royalty Pharma ( ($RPRX) ) has provided an announcement. On June 4, 2026, Royalty Pharma held its 2026...

23d ago

RPRX

Royalty Pharma Secures New $1.8 Billion Credit Facility

Royalty Pharma ( ($RPRX) ) has shared an announcement. On May 22, 2026, Royalty Pharma plc entered into...

1M ago

RPRX

Royalty Pharma price target raised to $64 from $63 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Royalty Pharma (RPRX) to $64 from $63 and keeps an...

2M ago

RPRX

Royalty Pharma price target raised to $58 from $50 at JPMorgan

JPMorgan raised the firm’s price target on Royalty Pharma (RPRX) to $58 from $50 and keeps an Overweight...

2M ago

RPRX

Royalty Pharma price target raised to $66 from $50 at Citi

Citi analyst Geoff Meacham raised the firm’s price target on Royalty Pharma (RPRX) to $66 from $50 and...

2M ago

RPRX

Royalty Pharma’s Earnings Call Signals Confident Growth

Royalty Pharma PLC (($RPRX)) has held its Q1 earnings call. Read on for the main highlights of the...

2M ago

RPRX

Royalty Pharma price target raised to $57 from $51 at UBS

UBS analyst Ashwani Verma raised the firm’s price target on Royalty Pharma (RPRX) to $57 from $51 and...

2M ago

RPRX

Royalty Pharma: Leveraged Biopharma Catalysts and De-Risked Royalty Growth Support Further Upside

Analyst Ashwani Verma from UBS maintained a Buy rating on Royalty Pharma and increased the price target to...

2M ago

RPRX

Royalty Pharma Expands Daraxonrasib Royalty Stake After Milestone

Royalty Pharma ( ($RPRX) ) has provided an update. On April 13, 2026, Revolution Medicines reported positive Phase...

3M ago

RPRX

Royalty Pharma price target raised to $63 from $61 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Royalty Pharma (RPRX) to $63 from $61...

3M ago

RPRX

Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804

Royalty Pharma (RPRX) announced a research and development co-funding agreement with Johnson & Johnson (JNJ) for a total...

3M ago

JNJ

RPRX

Zymeworks price target raised to $48 from $33 at Evercore ISI

Evercore ISI raised the firm’s price target on Zymeworks (ZYME) to $48 from $33 and keeps an Outperform...

4M ago

RPRX

ZYME

Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia

Royalty Pharma (RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective...

4M ago

RPRX

Zymeworks, Royalty Pharma enter $250M royalty-backed note financing

Zymeworks (ZYME) and Royalty Pharma (RPRX) announced an agreement for $250M in funding from Royalty Pharma in the...

4M ago

ONC

JAZZ

RPD FAQ

What was Royalty Pharma PLC’s price range in the past 12 months?

Royalty Pharma PLC lowest stock price was €28.87 and its highest was €49.00 in the past 12 months.

What is Royalty Pharma PLC’s market cap?

Royalty Pharma PLC’s market cap is €26.59B.

When is Royalty Pharma PLC’s upcoming earnings report date?

Royalty Pharma PLC’s upcoming earnings report date is Aug 12, 2026 which is in 46 days.

How were Royalty Pharma PLC’s earnings last quarter?

Royalty Pharma PLC released its earnings results on May 06, 2026. The company reported €1.104 earnings per share for the quarter, beating the consensus estimate of €1.034 by €0.07.

Is Royalty Pharma PLC overvalued?

According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Royalty Pharma PLC pay dividends?

Royalty Pharma PLC does not currently pay dividends.

What is Royalty Pharma PLC’s EPS estimate?

Royalty Pharma PLC’s EPS estimate is 1.09.

How many shares outstanding does Royalty Pharma PLC have?

Royalty Pharma PLC has 443,274,100 shares outstanding.

What happened to Royalty Pharma PLC’s price movement after its last earnings report?

Royalty Pharma PLC reported an EPS of €1.104 in its last earnings report, beating expectations of €1.034. Following the earnings report the stock price went down -0.465%.

Which hedge fund is a major shareholder of Royalty Pharma PLC?

Currently, no hedge funds are holding shares in DE:RPD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Royalty Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

12.67%

Trailing 12-Months

Asset Growth

12.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Royalty Pharma PLC

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma (RPD) Earnings & Revenues

Historic Earnings Reports

RPD Company Deck

RPD Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call was strongly positive: Royalty Pharma reported double-digit recurring revenue growth, attractive returns (ROIC ~14.1%, ROIE ~19.7%), robust cash generation ($722M portfolio cash flow), active capital deployment (>$0.5B) and strategic deal flow including R&D co-funding momentum (J&J and Teva deals) and high-impact clinical/regulatory wins (daraxonrasib, Avlayah, Myqorzo). Key risks highlighted were a material decline in milestone receipts (~53% drop), elevated interest expense timing, some market/policy headwinds (Promacta LOE, biosimilar Tysabri, MFN uncertainty) and optionality/execution risk in future co-funding tranches. Overall, the positive operating and balance-sheet trends and raised guidance outweigh the limited but meaningful risks discussed.View all DE:RPD earnings summaries

RPD Revenue Breakdown

93.34% Income from financial royalty assets

6.62% Other royalty income

0.04% Revenue from intangible royalty assets

RPD Stock 12 Month Forecast

Average Price Target

€51.80

▲(28.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"€26","34":"€34","42":"€42","50":"€50","58":"€58"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57.53238348,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€57.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.80405092571429,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€51.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.585139,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€43.59</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,34,42,50,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.52,46.44402949846154,47.36805899692308,48.29208849538462,49.216117993846154,50.14014749230769,51.064176990769234,51.98820648923077,52.91223598769231,53.83626548615385,54.760294984615385,55.68432448307692,56.608353981538464,{"y":57.53238348,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.52,46.00338853274726,46.48677706549451,46.97016559824176,47.45355413098901,47.93694266373627,48.420331196483524,48.90371972923077,49.38710826197803,49.870496794725284,50.35388532747253,50.83727386021979,51.32066239296704,{"y":51.80405092571429,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.52,45.37116453846154,45.22232907692308,45.07349361538462,44.92465815384615,44.77582269230769,44.62698723076923,44.47815176923077,44.32931630769231,44.18048084615385,44.03164538461538,43.88280992307692,43.73397446153846,{"y":43.585139,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.486,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.755,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.961,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.636,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.211,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.201,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.508,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.043,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.596,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.328,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.453,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.52,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >